Titre :

Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study

Auteur(s) :

Martin, Antoine [Auteur]
Nachury, Maria [Auteur]
Peyrin-Biroulet, Laurent [Auteur]
Bouhnik, Yoram [Auteur]
Nancey, Stéphane [Auteur]
Bourrier, Anne [Auteur]
Serrero, Melanie [Auteur]
Fumery, Mathurin [Auteur]
Buisson, Anthony [Auteur]
Laharie, David [Auteur]
Gilletta, Cyrielle [Auteur]
Filippi, Jerome [Auteur]
Allez, Matthieu [Auteur]
Bouguen, Guillaume [Auteur]
Roblin, Xavier [Auteur]
Altwegg, Romain [Auteur]
Dib, Nina [Auteur]
Pineton De Chambrun, Guillaume [Auteur]
Savoye, Guillaume [Auteur]
Carbonnel, Franck [Auteur]
Viennot, Stéphanie [Auteur]
Amiot, Aurelien [Auteur]

Titre de la revue :

Journal of Crohn's & colitis

Nom court de la revue :

J Crohns Colitis

Date de publication :

2020-01-13

ISSN :

1876-4479

Mot(s)-clé(s) :

vedolizumab
inflammatory bowel disease
ulcerative colitis
Crohn's disease

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

OBJECTIVE: It is unclear whether vedolizumab therapy can be discontinued in patients with inflammatory bowel disease [IBD] after achieving steroid-free clinical remission. The aim was to assess the risk of relapse after ...
Lire la suite >OBJECTIVE: It is unclear whether vedolizumab therapy can be discontinued in patients with inflammatory bowel disease [IBD] after achieving steroid-free clinical remission. The aim was to assess the risk of relapse after vedolizumab therapy was discontinued. METHODS: This was a retrospective observational study, collecting data from 21 tertiary centres affiliated with the GETAID from January 2017 to April 2019. Consecutive patients with IBD, who were in steroid-free clinical remission for at least 3 months and were treated with vedolizumab for at least 6 months, were included at the time of vedolizumab discontinuation. RESULTS: A total of 95 patients [58 with Crohn's disease] discontinued vedolizumab after a median duration of therapy of 17.5 [10.6-25.4] months. After a median follow-up period of 11.2 [5.8-17.7] months, 61 [64%] patients experienced disease relapse. The probabilities of relapse-free survival were 83%, 59%, and 36% at 6, 12, and 18 months, respectively. According to the multivariate analysis, a C-reactive protein level less than 5 mg/L at vedolizumab discontinuation (hazard ratio [HR] = 0.56, 95% confidence interval [CI] [0.33-0.95], p = 0.03) and discontinuation due to patients' elective choice (HR = 0.41, 95% CI [0.21-0.80], p = 0.009) were significantly associated with a lower risk of relapse. Re-treatment with vedolizumab was noted in 24 patients and provided steroid-free clinical remission in 71% and 62.5% at Week 14 and after a median follow-up of 11.0 [5.4-13.3] months, respectively, without any infusion reactions. CONCLUSIONS: In this retrospective study, two-thirds of patients with IBD treated with vedolizumab experienced relapse within the first year after vedolizumab discontinuation. Re-treatment with vedolizumab was effective in two-thirds of patients.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:48:20Z